The DOI matches its Crossref record; 113 of the 113 references it cites were found in a registry or an index.
Methods for the estimation of the National Institute for Health and Care Excellence cost-effectiveness threshold
Open accessAbstract
Background: Cost-effectiveness analysis involves the comparison of the incremental cost-effectiveness ratio of a new technology, which is more costly than existing alternatives, with the cost-effectiveness threshold. This indicates whether or not the health expected to be gained from its use exceeds the health expected to be lost elsewhere as other health-care activities are displaced. The threshold therefore represents the additional cost that has to be imposed on the system to forgo 1 quality-adjusted life-year (QALY) of health through displacement. There are no empirical estimates of the cost-effectiveness threshold used by the National Institute for Health and Care Excellence. Objectives: (1) To provide a conceptual framework to define the cost-effectiveness threshold and to provide the basis for its empirical estimation. (2) Using programme budgeting data for the English NHS, to estimate the relationship between changes in overall NHS expenditure and changes in mortality. (3) To extend this mortality measure of the health effects of a change in expenditure to life-years and to QALYs by estimating the quality-of-life (QoL) associated with effects on years of life and the additional direct impact on QoL itself. (4) To present the best estimate of the cost-effectiveness threshold for policy purposes. Methods: Earlier econometric analysis estimated the relationship between differences in primary care trust (PCT) spending, across programme budget categories (PBCs), and associated disease-specific mortality. This research is extended in several ways including estimating the impact of marginal increases or decreases in overall NHS expenditure on spending in each of the 23 PBCs. Further stages of work link the econometrics to broader health effects in terms of QALYs. Results: The most relevant ‘central’ threshold is estimated to be £12,936 per QALY (2008 expenditure, 2008–10 mortality). Uncertainty analysis indicates that the probability that the threshold is < £20,000 per QALY is 0.89 and the probability that it is < £30,000 per QALY is 0.97. Additional ‘structural’ uncertainty suggests, on balance, that the central or best estimate is, if anything, likely to be an overestimate. The health effects of changes in expenditure are greater when PCTs are under more financial pressure and are more likely to be disinvesting than investing. This indicates that the central estimate of the threshold is likely to be an overestimate for all technologies which impose net costs on the NHS and the appropriate threshold to apply should be lower for technologies which have a greater impact on NHS costs. Limitations: The central estimate is based on identifying a preferred analysis at each stage based on the analysis that made the best use of available information, whether or not the assumptions required appeared more reasonable than the other alternatives available, and which provided a more complete picture of the likely health effects of a change in expenditure. However, the limitation of currently available data means that there is substantial uncertainty associated with the estimate of the overall threshold. Conclusions: The methods go some way to providing an empirical estimate of the scale of opportunity costs the NHS faces when considering whether or not the health benefits associated with new technologies are greater than the health that is likely to be lost elsewhere in the NHS. Priorities for future research include estimating the threshold for subsequent waves of expenditure and outcome data, for example by utilising expenditure and outcomes available at the level of Clinical Commissioning Groups as well as additional data collected on QoL and updated estimates of incidence (by age and gender) and duration of disease. Nonetheless, the study also starts to make the other NHS patients, who ultimately bear the opportunity costs of such decisions, less abstract and more ‘known’ in social decisions. Funding: The National Institute for Health Research-Medical Research Council Methodology Research Programme.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The PHQ-9: Validity of a brief depression severity measure
Kroenke, K., Spitzer, R. L., & Williams, J. B. W. (2001) · Journal of General Internal Medicine · doi:10.1046/j.1525-1497.2001.016009606.x · Cited by 44,910
A Brief Measure for Assessing Generalized Anxiety Disorder: The GAD-7
Spitzer, R. L., Kroenke, K., Williams, J. B. W., & Löwe, B. (2006) · Archives of Internal Medicine · doi:10.1001/archinte.166.10.1092 · Cited by 31,765
Methods for the Economic Evaluation of Health Care Programmes
Drummond, M. E., Sculpher, M. J., Torrance, G. W., O’Brien, B. J., & Stoddart, G. L. (2005) · doi:10.1093/oso/9780198529446.001.0001 · Cited by 13,648
Self-citationInstrumental Variables Regression with Weak Instruments
Staiger, D., & Stock, J. H. (1997) · Econometrica · doi:10.2307/2171753 · Cited by 7,081
The World Health Report 2002 - Reducing Risks, Promoting Healthy Life
Not Available, N. A. (2003) · Education for Health: Change in Learning & Practice · doi:10.1080/1357628031000116808 · Cited by 6,046
Instrumental Variables Regression with Weak Instruments
Staiger, D., & Stock, J. (1994) · doi:10.3386/t0151 · Cited by 5,302
Bound, J., Jaeger, D. A., & Baker, R. M. (1995) · Journal of the American Statistical Association · doi:10.1080/01621459.1995.10476536 · Cited by 3,618
Tests for Specification Errors in Classical Linear Least-Squares Regression Analysis
Ramsey, J. B. (1969) · Journal of the Royal Statistical Society Series B: Statistical Methodology · doi:10.1111/j.2517-6161.1969.tb00796.x · Cited by 3,352
Testing for Weak Instruments in Linear IV Regression
Stock, J., & Yogo, M. (2002) · doi:10.3386/t0284 · Cited by 1,842
Laupacis, A., Feeny, D. H., Detsky, A. S., & Tugwell, P. (1992) · Europe PMC (PubMed Central) · Cited by 1,581
Testing Identifiability and Specification in Instrumental Variable Models
Cragg, J. G., & Donald, S. G. (1993) · Econometric Theory · doi:10.1017/s0266466600007519 · Cited by 1,412
Durbin, J. (1954) · Revue de l'Institut International de Statistique / Review of the International Statistical Institute · doi:10.2307/1401917 · Cited by 1,269
Conley, T. G., Hansen, C. B., & Rossi, P. E. (2012) · Review of Economics and Statistics · doi:10.1162/rest_a_00139 · Cited by 1,161
Clozapine-induced agranulocytosis. incidence and risk factors in the united states
Alvir, J. M. J., Lieberman, J. A., Safferman, A. Z., Schwimmer, J. L., & Schaaf, J. A. (1993) · New England Journal of Medicine · doi:10.1056/nejm199307153290303 · Cited by 967
Rutten, F., Bleichrodt, H., Brouwer, W., Koopmanschap, M., & Schut, E. (2001) · Journal of Health Economics · doi:10.1016/s0167-6296(01)00097-2 · Cited by 963
Claxton, K. (1999) · Journal of Health Economics · doi:10.1016/s0167-6296(98)00039-3 · Cited by 889
Self-citationThe NICE Cost-Effectiveness Threshold: What it is and What that Means
McCabe, C., Claxton, K., & Culyer, A. J. (2008) · PharmacoEconomics · doi:10.2165/00019053-200826090-00004 · Cited by 864
Self-citationWillingness to Pay for a Quality-adjusted Life Year: In Search of a Standard
Hirth, R. A., Chernew, M. E., Miller, E., Fendrick, A. M., & Weissert, W. G. (2000) · Medical Decision Making · doi:10.1177/0272989x0002000310 · Cited by 850
Instrument Relevance in Multivariate Linear Models: A Simple Measure
Shea, J. (1997) · Review of Economics and Statistics · doi:10.1162/rest.1997.79.2.348 · Cited by 824
Eichler, H.-G., Kong, S. X., Gerth, W. C., Mavros, P., & Jönsson, B. (2004) · Value in Health · doi:10.1111/j.1524-4733.2004.75003.x · Cited by 788
Economic foundations of cost-effectiveness analysis
Garber, A. M., & Phelps, C. E. (1997) · Journal of Health Economics · doi:10.1016/s0167-6296(96)00506-1 · Cited by 766
National Institute for Clinical Excellence and its value judgments
Rawlins, M. D., & Culyer, A. J. (2004) · BMJ · doi:10.1136/bmj.329.7459.224 · Cited by 765
Devlin, N., & Parkin, D. (2004) · Health Economics · doi:10.1002/hec.864 · Cited by 709
Self-citationShiroiwa, T., Sung, Y., Fukuda, T., Lang, H., Bae, S., & Tsutani, K. (2010) · Health Economics · doi:10.1002/hec.1481 · Cited by 690
Health-related quality of life measurement for evaluation research and policy analysis.
Kaplan, R. M., & Bush, J. W. (1982) · Health Psychology · doi:10.1037/0278-6133.1.1.61 · Cited by 666
Assessing cost-effectiveness in healthcare: history of the $50,000 per QALY threshold
Grosse, S. D. (2008) · Expert Review of Pharmacoeconomics & Outcomes Research · doi:10.1586/14737167.8.2.165 · Cited by 637
A social tariff for EuroQol: results from a UK general population surveyPreprint
Dolan, P., Gudex, C. M., Kind, P., & Williams, A. (1995) · RePEc: Research Papers in Economics · Cited by 611
What Is the Price of Life and Why Doesn't It Increase at the Rate of Inflation?
Ubel, P. A., Hirth, R. A., Chernew, M. E., & Fendrick, A. M. (2003) · Archives of Internal Medicine · doi:10.1001/archinte.163.14.1637 · Cited by 588
QALY maximisation and people's preferences: a methodological review of the literature
Dolan, P., Shaw, R., Tsuchiya, A., & Williams, A. (2005) · Health Economics · doi:10.1002/hec.924 · Cited by 431
Nixon, J., & Ulmann, P. (2006) · The European Journal of Health Economics · doi:10.1007/s10198-005-0336-8 · Cited by 418
Exploring the Effects of Health Care on Mortality Across OECD Countries
(2001) · OECD Labour Market and Social Policy Occasional Papers · doi:10.1787/716472585704 · Cited by 393
Kaltenthaler, E., Brazier, J., De Nigris, E., Tumur, I., Ferriter, M., Beverley, C., Parry, G., Rooney, G., & Sutcliffe, P. (2006) · Health Technology Assessment · doi:10.3310/hta10330 · Cited by 357
Getting the Most out of PROMs: Putting Health Outcomes at the Heart of NHS Decision-Making
Devlin, N. J., & Appleby, J. (2010) · Monographs · Cited by 343
Self-citationThe Medical Expenditure Panel Survey: a national health information resource.
(1996) · PubMed · Cited by 338
Health care spending as determinants of health outcomes
Crémieux, P., Ouellette, P., & Pilon, C. (1999) · Health Economics · Cited by 295
Government health expenditures and health outcomes
Bokhari, F. A. S., Gai, Y., & Gottret, P. (2007) · Health Economics · doi:10.1002/hec.1157 · Cited by 291
On the decision rules of cost-effectiveness analysis
Johannesson, M., & Weinstein, M. C. (1993) · Journal of Health Economics · doi:10.1016/0167-6296(93)90005-y · Cited by 288
Rosenheck, R. A., Leslie, D. L., Sindelar, J., Miller, E. A., Lin, H., Stroup, T. S., McEvoy, J., Davis, S. M., Keefe, R. S. E., Swartz, M., et al. (2006) · American Journal of Psychiatry · doi:10.1176/ajp.2006.163.12.2080 · Cited by 281
Critical ratios and efficient allocation
Weinstein, M., & Zeckhauser, R. (1973) · Journal of Public Economics · doi:10.1016/0047-2727(73)90002-9 · Cited by 278
Baker, R., Bateman, I., Donaldson, Jones-Lee, M., Lancsar, E., Loomes, G., Mason, H., Odejar, M., Pinto Prades, J., Robinson, A., et al. (2010) · Health Technology Assessment · doi:10.3310/hta14270 · Cited by 276
NICE's cost effectiveness threshold
Appleby, J., Devlin, N., & Parkin, D. (2007) · BMJ · doi:10.1136/bmj.39308.560069.be · Cited by 257
Self-citationIncremental cost-effectiveness ratios (ICERs): The silence of the lambda
Gafni, A., & Birch, S. (2006) · Social Science & Medicine · doi:10.1016/j.socscimed.2005.10.023 · Cited by 251
Avoiding the Unintended Consequences of Growth in Medical Care: How Might More Be Worse?
Fisher, E. S., & Welch, H. G. (1999) · JAMA · doi:10.1001/jama.281.5.446 · Cited by 251
Cost-effectiveness league tables: More harm than good?
Drummond, M., Torrance, G., & Mason, J. (1993) · Social Science & Medicine · doi:10.1016/0277-9536(93)90315-u · Cited by 249
Value based pricing for NHS drugs: an opportunity not to be missed?
Claxton, K., Briggs, A., Buxton, M. J., Culyer, A. J., McCabe, C., Walker, S., & Sculpher, M. J. (2008) · BMJ · doi:10.1136/bmj.39434.500185.25 · Cited by 230
Self-citationCrawford, M. J., Killaspy, H., Barnes, T. R. E., Barrett, B., Byford, S., Clayton, K., Dinsmore, J., Floyd, S., Hoadley, A., Johnson, T., et al. (2012) · BMJ · doi:10.1136/bmj.e846 · Cited by 230
King, J. T., Tsevat, J., Lave, J. R., & Roberts, M. S. (2005) · Medical Decision Making · doi:10.1177/0272989x05282640 · Cited by 219
Discounting and decision making in the economic evaluation of health-care technologies
Claxton, K., Paulden, M., Gravelle, H., Brouwer, W., & Culyer, A. J. (2011) · Health Economics · doi:10.1002/hec.1612 · Cited by 212
Self-citationHaas, S. J., Hill, R., Krum, H., Liew, D., Tonkin, A., Demos, L., Stephan, K., & McNeil, J. (2007) · Drug Safety · doi:10.2165/00002018-200730010-00005 · Cited by 197
An Empiric Estimate of the Value of Life: Updating the Renal Dialysis Cost-Effectiveness Standard
Lee, C. P., Chertow, G. M., & Zenios, S. A. (2009) · Value in Health · doi:10.1111/j.1524-4733.2008.00401.x · Cited by 196
Does health care spending improve health outcomes? Evidence from English programme budgeting data
Martin, S., Rice, N., & Smith, P. C. (2008) · Journal of Health Economics · doi:10.1016/j.jhealeco.2007.12.002 · Cited by 191
Self-citationA systematic review of atypical antipsychotic drugs in schizophrenia
Bagnall, A. M., Jones, L., Ginnelly, L., Lewis, R., Glanville, J., Gilbody, S., Davies, L., Torgerson, D., & Kleijnen, J. (2003) · Health Technology Assessment · doi:10.3310/hta7130 · Cited by 178
Gafni, A., & Birch, S. (1993) · Europe PMC (PubMed Central) · Cited by 175
Culyer, A., McCabe, C., Briggs, A., Claxton, K., Buxton, M., Akehurst, R., Sculpher, M., & Brazier, J. (2007) · Journal of Health Services Research & Policy · doi:10.1258/135581907779497567 · Cited by 173
Self-citationSensitivity Analysis for Instrumental Variables Regression With Overidentifying Restrictions
Small, D. S. (2007) · Journal of the American Statistical Association · doi:10.1198/016214507000000608 · Cited by 171
Mathematical programming for the efficient allocation of health care resources
Stinnett, A. A., & Paltiel, A. D. (1996) · Journal of Health Economics · doi:10.1016/s0167-6296(96)00493-6 · Cited by 163
Gyrd‐Hansen, D. (2003) · Health Economics · doi:10.1002/hec.799 · Cited by 158
Green, C., & Gerard, K. (2008) · Health Economics · doi:10.1002/hec.1414 · Cited by 155
Is there a kink in consumers' threshold value for cost‐effectiveness in health care?
OʼBrien, B. J., Герцен, К. А., Willan, A. R., & Faulkner, A. (2002) · Health Economics · doi:10.1002/hec.655 · Cited by 155
Pharmacoeconomics: NICE's approach to decision-making
Rawlins, M., Barnett, D., & Stevens, A. (2010) · British Journal of Clinical Pharmacology · doi:10.1111/j.1365-2125.2009.03589.x · Cited by 152
Editorial: Some reflections on cost-effectiveness analysis
Johannesson, M., & Meltzer, D. O. (1998) · Health Economics · Cited by 141
The Salford Family Intervention Project: Relapse Rates of Schizophrenia at Five and Eight Years
Tarrier, N., Barrowclough, C., Porceddu, K., & Fitzpatrick, E. (1994) · The British Journal of Psychiatry · doi:10.1192/bjp.165.6.829 · Cited by 141
Hollinghurst, S., Peters, T. J., Kaur, S., Wiles, N., Lewisand, G., & Kessler, D. (2010) · British Journal of Psychiatry · doi:10.1192/bjp.bp.109.073080 · Cited by 123
Willingness to Pay for a Quality-Adjusted Life-Year: The Individual Perspective
Bobinac, A., van Exel, J. N. A., Rutten, F., & Brouwer, W. B. F. (2010) · Value in Health · doi:10.1111/j.1524-4733.2010.00781.x · Cited by 122
Claxton, K., Palmer, S., Longworth, L., Bojke, L., Griffin, S. C., McKenna, C., Soares, M. O., Spackman, E., & Youn, J.-H. (2012) · Health Technology Assessment · doi:10.3310/hta16460 · Cited by 119
Self-citationIdentifying existing health care services that do not provide value for money
Elshaug, A. G., Moss, J. R., Littlejohns, P., Karnon, J. D., Merlin, T., & Hiller, J. E. (2009) · The Medical Journal of Australia · doi:10.5694/j.1326-5377.2009.tb02394.x · Cited by 118
Diagnostics for IV Regressions
Pesaran, M. H., & Taylor, L. W. (1999) · Oxford Bulletin of Economics and Statistics · doi:10.1111/1468-0084.00128 · Cited by 116
Gyrd‐Hansen, D. (2005) · PharmacoEconomics · doi:10.2165/00019053-200523050-00002 · Cited by 113
Kaltenthaler, E., Shackley, P., Stevens, K., Beverley, C., Parry, G., & Chilcott, J. (2002) · Health Technology Assessment · doi:10.3310/hta6220 · Cited by 109
Davies, L. M., Lewis, S. W., Jones, P. B., Barnes, T. R. E., Gaughran, F., Hayhurst, K. P., Markwick, A., & Lloyd, H. M. (2007) · The British Journal of Psychiatry · doi:10.1192/bjp.bp.106.028654 · Cited by 109
Trying to estimate a monetary value for the QALY
Prades, J. L. P., Loomes, G., & Brey, R. (2009) · Journal of Health Economics · doi:10.1016/j.jhealeco.2009.02.003 · Cited by 103
How much will Herceptin really cost?
Barrett, A., Roques, T. W., Small, M., & Smith, R. (2006) · BMJ · doi:10.1136/bmj.39008.624051.be · Cited by 101
Searching for cost effectiveness thresholds in the NHS
Appleby, J., Devlin, N. J., Parkin, D. W., Buxton, M. J., & Chalkidou, K. (2009) · Health Policy · doi:10.1016/j.healthpol.2008.12.010 · Cited by 100
Self-citationA Framework for Addressing Structural Uncertainty in Decision Models
Jackson, C. H., Bojke, L., Thompson, S. G., Claxton, K., & Sharples, L. D. (2011) · Medical Decision Making · doi:10.1177/0272989x11406986 · Cited by 100
Self-citationGlobal Burden of Disease Study 2010
Prados, D. G. (2012) · Cited by 99
Currie, C. J., McEwan, P. C., Peters, J. R., Patel, T. C., & Dixon, S. (2005) · Value in Health · doi:10.1111/j.1524-4733.2005.00046.x · Cited by 98
Should NICE's threshold range for cost per QALY be raised? Yes
Towse, A. (2009) · BMJ · doi:10.1136/bmj.b181 · Cited by 92
Kendrick, T., Chatwin, J., Dowrick, C., Tylee, A., Morriss, R., Peveler, R., Leese, M., McCrone, P., Harris, T., Moore, M., et al. (2009) · Health Technology Assessment · doi:10.3310/hta13220 · Cited by 86
Hatziandreu, E. J., Brown, R. E., Revicki, D. A., Turner, R. R., Martindale, J. J., Levine, S., & Siegel, J. E. (1994) · PharmacoEconomics · doi:10.2165/00019053-199405030-00008 · Cited by 85
Peveler, R. C., Kendrick, T., Buxton, M., Longworth, L., Baldwin, D. S., Moore, M. V., Chatwin, J., Goddard, J. R., Thornett, A. M., Smith, H. E., et al. (2005) · Health Technology Assessment · doi:10.3310/hta9160 · Cited by 83
Birch, S., & Gafni, A. (2005) · Journal of Health Services Research & Policy · doi:10.1258/135581906775094235 · Cited by 79
Bridges, J. F. P., Onukwugha, E., & Mullins, C. D. (2010) · PharmacoEconomics · doi:10.2165/11530650-000000000-00000 · Cited by 76
Cost-effectiveness ratios: in a league of their own
Birch, S., & Gafni, A. (1994) · Health Policy · doi:10.1016/0168-8510(94)90031-0 · Cited by 70
Willingness to Pay per Quality-Adjusted Life Year in a Study of Knee Osteoarthritis
Byrne, M. M., O’Malley, K. J., & Suarez-Almazor, M. E. (2005) · Medical Decision Making · doi:10.1177/0272989x05282638 · Cited by 70
Efficiency, Equity, and Budgetary Policies
Epstein, D. M., Chalabi, Z., Claxton, K., & Sculpher, M. (2007) · Medical Decision Making · doi:10.1177/0272989x06297396 · Cited by 69
Self-citationSoares, M. O., Bojke, L., Dumville, J. C., Iglesias, C. P., Cullum, N. A., & Claxton, K. (2011) · Statistics in Medicine · doi:10.1002/sim.4288 · Cited by 63
Self-citationDoes Medicare Have an Implicit Cost-Effectiveness Threshold?
Chambers, J. D., Neumann, P. J., & Buxton, M. J. (2010) · Medical Decision Making · doi:10.1177/0272989x10371134 · Cited by 63
Cost-Effectiveness League Tables
Mauskopf, J., Rutten, F., & Schonfeld, W. H. (2003) · PharmacoEconomics · doi:10.2165/00019053-200321140-00001 · Cited by 62
Gutacker, N., Bojke, C., Daidone, S., Devlin, N. J., Parkin, D. W., & Street, A. (2012) · Health Economics · doi:10.1002/hec.2871 · Cited by 60
Self-citationCan we estimate the ‘social’ value of a QALY?
Smith, R. D., & Richardson, J. R. J. (2005) · Health Policy · doi:10.1016/j.healthpol.2004.12.009 · Cited by 59
Lieu, T. A., Ray, G. T., Ortega‐Sanchez, I. R., Kleinman, K., Rusinak, D., & Prosser, L. A. (2009) · PharmacoEconomics · doi:10.2165/11314000-000000000-00000 · Cited by 57
New-onset type-2 diabetes associated with atypical antipsychotic medications
Lambert, M. T., Copeland, L. A., Sampson, N., & Duffy, S. A. (2006) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2006.02.007 · Cited by 55
Comparing costs and outcomes across programmes of health care
Martin, S., Rice, N., & Smith, P. (2011) · Health Economics · doi:10.1002/hec.1716 · Cited by 52
Self-citationSimon, J., Pilling, S., Burbeck, R., & Goldberg, D. P. (2006) · The British Journal of Psychiatry · doi:10.1192/bjp.bp.105.014571 · Cited by 48
Budget allocation and the revealed social rate of time preference for health
Paulden, M., & Claxton, K. (2011) · Health Economics · doi:10.1002/hec.1730 · Cited by 47
Self-citationShould NICE's threshold range for cost per QALY be raised? No
Raftery, J. P. (2009) · BMJ · doi:10.1136/bmj.b185 · Cited by 46
Kendrick, T., Peveler, R., Longworth, L., Baldwin, D. S., Moore, M. V., Chatwin, J., Thornett, A. M., Goddard, J. R., Campbell, M. J., Smith, H. E., et al. (2006) · The British Journal of Psychiatry · doi:10.1192/bjp.188.4.337 · Cited by 42
New drugs for old: disinvestment and NICE
Hughes, D. A., & Ferner, R. E. (2010) · BMJ · doi:10.1136/bmj.c572 · Cited by 40
Davies, L. M., Barnes, T. R. E., Jones, P. B., Lewis, S. W., Gaughran, F., Hayhurst, K. P., Markwick, A., & Lloyd, H. M. (2008) · Value in Health · doi:10.1111/j.1524-4733.2007.00280.x · Cited by 39
Knapp, M. R. J., Windmeijer, F., Brown, J., Kontodimas, S., Tzivelekis, S., Haro, J. M., Ratcliffe, M., Hong, J., & Novick, D. (2008) · PharmacoEconomics · doi:10.2165/00019053-200826040-00006 · Cited by 37
Cognitive behaviour therapy for improving social recovery in psychosis: Cost-effectiveness analysis
Barton, G., Hodgekins, J., Mugford, M., Jones, P. B., Croudace, T. J., & Fowler, D. G. (2009) · Schizophrenia Research · doi:10.1016/j.schres.2009.03.041 · Cited by 31
The $64,000 question—What is a quality-adjusted life-year worth?
Rascati, K. L. (2006) · Clinical Therapeutics · doi:10.1016/j.clinthera.2006.07.002 · Cited by 30
Economic Evaluation and Cost-Effectiveness Thresholds
(2009) · doi:10.2165/11313750-000000000-00000 · Cited by 28
Groot, W. N. J., & van den Brink, H. M. (2008) · BMC Health Services Research · doi:10.1186/1472-6963-8-136 · Cited by 25
How much are health-care systems prepared to pay to produce a QALY?
Buxton, M. J. (2005) · The European Journal of Health Economics · doi:10.1007/s10198-005-0325-y · Cited by 22
Thresholds in Cost-Effectiveness Analysis—More of the Story
Laufer, F. N. (2005) · Value in Health · doi:10.1111/j.1524-4733.2005.08103.x · Cited by 18
Lenox‐Smith, A., Greenstreet, L., Burslem, K., & Knight, C. (2009) · Clinical Drug Investigation · doi:10.2165/00044011-200929030-00004 · Cited by 16
Einstein on Willingness to Pay per QALY: Is There a Better Way?
Johnson, F. R. (2005) · Medical Decision Making · doi:10.1177/0272989x05283084 · Cited by 14
Polsky, D. E. (2005) · Medical Decision Making · doi:10.1177/0272989x05283136 · Cited by 13
Treating negative symptoms of schizophrenia
Kendall, T. (2012) · BMJ · doi:10.1136/bmj.e664 · Cited by 12
Yaesoubi, R., & Roberts, S. D. (2010) · Health Care Management Science · doi:10.1007/s10729-010-9135-6 · Cited by 8
Re: How Much Is Life Worth: Cetuximab, Non-Small Cell Lung Cancer, and the $440 Billion Question
Cohen, J. L., & Looney, W. (2010) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djq246 · Cited by 5
Assessing the Performance of the EQ-VAS in the NHS PROMs ProgrammePreprint
Feng, Y., Parkin, D. W., & Devlin, N. J. (2015) · SSRN Electronic Journal · doi:10.2139/ssrn.2633442 · Cited by 3
Self-citation
Research works printed but not linked: 70
- 2008, Guide to the Methods of Technological Appraisal
- 2008, NICE: First report of the Health Committee 2007–2008
- 2004, Guide to the Methods of Technological Appraisal
- Williams, 2004, What Could be Nicer than NICE? OHE Annual Lecture
- Birch, 1993, Changing the problem to fit the solution: Johannesson and Weinstein’s (mis) application of economics to real world problems, J Health Econ, 12, 469, 10.1016/0167-6296(93)90006-Z · doi:10.1016/0167-6296(93)90006-z
- 2010, A New Value-Based Approach to the Pricing of Branded Medicines – a Consultation
- 2008, First Report of the Health Committee 2007–2008
- Abelson, 2003, The value of life and health for public policy, Econ Record, 79, S2, 10.1111/1475-4932.00087 · doi:10.1111/1475-4932.00087
- Johnson, 2006, Eliciting stated preferences for health-technology adoption criteria using paired comparisons and recommendation judgments, Value Health, 9, 303, 10.1111/j.1524-4733.2006.00119.x · doi:10.1111/j.1524-4733.2006.00119.x
- Mason, 2009, Modelling the monetary value of a qaly: a new approach based on UK data, Health Econ, 18, 933, 10.1002/hec.1416 · doi:10.1002/hec.1416
- Haninger, 2006, Willingness to Pay for Quality-Adjusted Life Years: Empirical Inconsistency Between Cost-effectiveness Analysis and Economic Welfare Theory
- Claxton, 2010, Appropriate Perspectives for Heath Care Decisions. CHE Research Paper 54
- Tappenden, 2007, A stated preference binary choice experiment to explore NICE decision making, Pharmacoeconomics, 25, 685, 10.2165/00019053-200725080-00006 · DOI
- 2009, Appraising Life Extending End-of-Life Treatments
- 2012, Draft Guide to the Methods of Technology Appraisal
- 2008, NICE Response to the First Report of Session 2007–2008
- 2008, The Government’s Response to the Health Select Committee’s First Report of Session 2007–08 on the National Institute for Health and Care Excellence
- Collier, 2008, Parliamentary review asks NICE to do better still, BMJ, 336, 53, 10.1136/bmj.39454.496748.80 · doi:10.1136/bmj.39454.496748.80
- Martin, 2007, The Link Between Health Care Spending and Health Outcomes: Evidence from English Programme Budgeting Data. CHE Research Paper 24
- Martin, 2007, Further Evidence on the Link Between Health Care Spending and Health Outcomes in England. CHE Research Paper 32
- Martin, 2008, The Link Between Health Care Spending and Health Outcomes for the New English Primary Care Trusts. CHE Research Paper 42
- Martin, 2009, How Good at Commissioning Health are English Primary Care Trusts? A Preliminary Statistical Analysis. Report to the Health Foundation
- Martin, 2010, Panel Data Estimates of the Link Between Health Care Spending and Health Outcomes for English Primary Care Trusts
- Cochrane, 1997, Health service ‘input’ and mortality ‘output’ in developed countries, J Epidemiol Community Health, 51, 344, 10.1136/jech.51.4.344 · doi:10.1136/jech.51.4.344
- Young, 2001, An explanation of the persistent doctor–mortality association, J Epidemiol Community Health, 55, 80, 10.1136/jech.55.2.80 · doi:10.1136/jech.55.2.80
- St Leger, 2001, The anomaly that finally went away?, J Epidemiol Community Health, 55, 79, 10.1136/jech.55.2.79 · doi:10.1136/jech.55.2.79
- Nolte, 2004, Does Health Care Save Lives
- Gravelle, 1987, International cross-section analysis of the determination of mortality, Soc Sci Med, 25, 427, 10.1016/0277-9536(87)90167-5 · doi:10.1016/0277-9536(87)90167-5
- Moreno-Serra, 2011, The Effects of Health Coverage on Population Outcomes: A Country-Level Panel Data analysis
- 2009, PCT Recurrent Revenue Allocations Exposition Book: 2009/10 and 2010/11
- Smith, 2001, Capitation funding in the public sector, J R Stat Soc Series A, 164, 217, 10.1111/1467-985X.00200 · doi:10.1111/1467-985x.00200
- 2005, Recurrent Resource Allocations: 2006/07, 2007/08
- 2008, Good Governance Report: Review of Programme Budgeting
- Appleby, 2011, Explaining Variations in Primary Care Trusts’ Spending on Cancer Services
- Lakhani, 2006, Compendium of Clinical and Health Indicators: Data Definitions and User Guide for Computer Files
- 2005, Census 2001: General Report for England and Wales
- Dixon, 2011, A person based formula for allocating commissioning funds to general practices in England: development of a statistical model, BMJ, 343, d6608, 10.1136/bmj.d6608 · doi:10.1136/bmj.d6608
- Curtis, 2011, Unit Costs of Health and Social Care 2011
- Wailoo, 2010, The Incorporation of Health Benefits in Cost Utility Analysis Using the EQ-5D: Report by the Decision Support Unit
- Claxton, 2011, Value-based Pricing for Pharmaceuticals: Its Role, Specification and Prospects in a Newly Devolved NHS. CHE Research Paper 60
- Maynard, 2006, Seven years of feast, seven years of famine: boom to bust in the NHS?, BMJ, 332, 906, 10.1136/bmj.332.7546.906 · doi:10.1136/bmj.332.7546.906
- 2007, The Pharmaceutical Price Regulation Scheme. An OFT Market Study. VBP Report 2007
- 2011, TA237: Ranibizumab for the Treatment of Diabetic Macular Oedema
- 2012, Macular Oedema (Diabetic) – Ranibizumab (Rapid Review of TA237): Appraisal Consultation Document
- 2010, Single Technology Appraisal (STA) Manufacturer Submission: Lucentis® (Ranibizumab) for the Treatment of Visual Impairment due to Diabetic Macular Oedema (DMO)
- Broome, 1978, Trying to value a life, J Public Econ, 9, 91, 10.1016/0047-2727(78)90029-4 · doi:10.1016/0047-2727(78)90029-4
- Brock, 2006, How much is more life worth?, Hastings Cent Rep, 36, 17, 10.1353/hcr.2006.0036 · doi:10.1353/hcr.2006.0036
- Brouwer, 2008, The new myth – the social value of the QALY, Pharmacoeconomics, 26, 1, 10.2165/00019053-200826010-00001 · doi:10.2165/00019053-200826010-00001
- Maynard, 2010, The future role of NICE, BMJ, 341, 1006, 10.1136/bmj.c6286 · doi:10.1136/bmj.c6286
- Towse, 2002, Cost-Effectiveness Thresholds: Economic and Ethical Issues
- Speight, 2009, Wouldn’t it be NICE to consider patients’ views when rationing health care?, BMJ, 338, 297, 10.1136/bmj.b85 · doi:10.1136/bmj.b85
- Mason, 2009, Public funding of new cancer drugs: is NICE getting nastier?, Eur J Cancer, 45, 1188, 10.1016/j.ejca.2008.11.040 · doi:10.1016/j.ejca.2008.11.040
- Wooldridge, 2002, Econometric Analysis of Cross Section and Panel Data
- 2007, Payment by Results: Tariff Information
- 2005, Unified Exposition Book: 2003/04, 2004/05 and 2005/06 PCT Revenue Resource Limits
- Dixon, 2011, A person based formula for allocating commissioning funds to general practices in England: development of a statistical model, BMJ, 343, d6608, 10.1136/bmj.d6608 · doi:10.1136/bmj.d6608
- Kovandic, 2008, Estimating the Causal Effect of Gun Prevalence on Homicide Rates: A Local Average Treatment Effect Approach
- 2011, Provisional Monthly Patient Reported Outcome Measures (PROMs) in England: A Guide to PROMs Methodology
- 2012, Guide to the Methods of Technological Appraisal
- Murray, 1996, The Global Burden of Disease
- 2008, The Global Burden of Disease: 2004 Update
- Mathers, 2003, Global Burden of Disease in 2002: Data Sources, Methods and Results
- 2012, Provisional Monthly Patient Reported Outcome Measures (PROMs) in England
- 2009, CG82: Core Interventions in the Treatment and Management of Schizophrenia in Primary and Secondary Care
- 2009, CG90: Depression the Treatment and Management of Depression in Adults
- Mears, 2008, Progress on NICE guideline implementation in mental health trusts: meta-analyses, Psychiatrist, 32, 383
- Jarbrink, 2009, Quality of life and drug costs associated with switching antipsychotic medication to once-daily extended release quetiapine fumarate in patients with schizophrenia, Curr Med Res Opin, 25, 709, 10.1185/03007990902738810 · doi:10.1185/03007990902738810
- 2009, CG82: Schizophrenia (Update)
- 2007, CG90: Depression in Adults: The Treatment and Management of Depression in Adults
- 2011, A New Value-Based Approach to the Pricing of Branded Medicines: Government Response to Consultation
Cited by
Country-Level Cost-Effectiveness Thresholds: Initial Estimates and the Need for Further Research
Woods, B., Revill, P., Sculpher, M., & Claxton, K. (2016) · Value in Health · doi:10.1016/j.jval.2016.02.017 · Cited by 884
Self-citationCost–effectiveness thresholds: pros and cons
Bertram, M., Lauer, J., De Joncheere, K., Edejer, T., Hutubessy, R., Kieny, M.-P., & Hill, S. (2016) · Bulletin of the World Health Organization · doi:10.2471/blt.15.164418 · Cited by 783
Return on investment of public health interventions: a systematic review
Masters, R., Anwar, E., Collins, B., Cookson, R., & Capewell, S. (2017) · Journal of Epidemiology and Community Health · doi:10.1136/jech-2016-208141 · Cited by 480
Ochalek, J., Lomas, J., & Claxton, K. (2018) · BMJ Global Health · doi:10.1136/bmjgh-2018-000964 · Cited by 334
Self-citationWilkinson, T., Sculpher, M. J., Claxton, K., Revill, P., Briggs, A., Cairns, J. A., Teerawattananon, Y., Asfaw, E., Lopert, R., Culyer, A. J., et al. (2016) · Value in Health · doi:10.1016/j.jval.2016.04.015 · Cited by 327
Self-citation
Metadata
- Authors
- Claxton, K., Martin, S., Soares, M., Rice, N., Spackman, E., Hinde, S., Devlin, N., Smith, P. C., & Sculpher, M.
- Venue
- Health Technology Assessment
- Published
- 2015-02
- Volume
- 19
- Issue
- 14
- Pages
- 1-504
- ISSN
- 1366-5278 (ISSN-L)
- 2046-4924
- OpenAlex
- W166560170
- Cited by
- 853
- References
- 113
- FWCI
- 204.22
- Type
- journal article
- Language
- en
- Open access
- diamond
- Funders
- National Institute for Health Research (06/92/54)
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.